Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?

about

Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?

Item

http://www.wikidata.org/entity/Q39412362

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Does BMI, gender or age affect ...... agement of overactive bladder?

@en

Does BMI, gender or age affect ...... agement of overactive bladder?

@nl

type

Item

label

Does BMI, gender or age affect ...... agement of overactive bladder?

@en

Does BMI, gender or age affect ...... agement of overactive bladder?

@nl

prefLabel

Does BMI, gender or age affect ...... agement of overactive bladder?

@en

Does BMI, gender or age affect ...... agement of overactive bladder?

@nl

P1476

Does BMI, gender or age affect ...... agement of overactive bladder?

@en

P2093

Christopher R Chapple

http://www.w3.org/2001/XMLSchema#string

Emad Siddiqui

http://www.w3.org/2001/XMLSchema#string

Linda Cardozo

http://www.w3.org/2001/XMLSchema#string

Robert Snijder

http://www.w3.org/2001/XMLSchema#string

Sender Herschorn

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic review of overweight and obesity as risk factors and targets for clinical intervention for urinary incontinence in women

Solifenacin significantly improves all symptoms of overactive bladder syndrome.

Effects of obesity and weight loss in patients with nononcological urological disease.

Obesity and urinary incontinence: epidemiology and clinical research update.

Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.

Weight loss: a novel and effective treatment for urinary incontinence

Solifenacin at 3 years: a review of efficacy and safety.

Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder.

Determinants of urinary incontinence in a population of young and middle-aged women.

Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females.

P2888

s00192-016-3130-5

P304

477-488

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1007/S00192-016-3130-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27605255

http://www.w3.org/2001/XMLSchema#string